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Adeno-associated virus (AAV) has emerged as the vector of choice for safe, efficacious and potent gene 
therapy. With increasing clinical successes, demands for high-quality, robust, cost-effective cGMP supplies of 
viral vector are soaring. Bioprocess engineers and manufacturers are tasked to meet these growing needs and 
are challenged to find solutions that can evolve at the same pace as evolving therapies. Lonza is developing 
and implementing solutions to meet the clinical supply demand in its flexible, multi-product facility, and can 
accommodate a variety of production systems (transfection, producer cell line, recombinant baculovirus or 
herpesvirus-mediated) from raw materials to the final filled drug product. The advantages and disadvantages of 
the production systems will be discussed.  
 
Lonza offers a platform process for AAV production using the recombinant baculovirus-based system; features, 
benefits and challenges will be described. The baculovirus-based process offers scalability to generate large 
batches of AAV while maintaining the critical quality attributes of the drug product, as supported by Lonza-
manufactured batches produced and released under cGMP conditions.   
 
To ensure quality, Lonza has isolated and characterized a clonal Sf9 cell population to generate recombinant 
baculovirus seed stocks and master virus banks.  Using the platform process, Lonza can generate high titers of 
AAV, up to 1E12 vector genomes/mL in the production culture, in either rocking-motion or stirred-tank 
bioreactors to the desired scale. Downstream processing consists of a scalable column purification with 
enrichment of up to 95% of full capsids in the final bulk drug substance. One of the current challenges to 
downstream processing includes identification of affinity resins to meet serotype diversity of AAV products. To 
complement the manufacturing platform, Lonza has developed a set of analytical tools to measure in-process 
and final drug product quantity, quality, purity and process residuals.  
 
As the field evolves towards the use of novel synthetic, hybrid or modified capsids to increase tissue specificity, 
transduction efficiency and/or overcome pre-existing immunity to common AAV serotypes, Lonza has 
successfully faced challenges in the manufacture of these capsids in the baculovirus-based AAV production 
process. To demonstrate Lonza’s ability to address these challenges, a case study showing identification of a 
product-related impurity and the process-based resolution will be presented. 
 
 
